Search clinical trials for: Ligand Dependency

Total 691 results

Hoffmann-La Roche

Completed

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

Neoplasms | Head and Neck Neoplasms | Colorectal Neoplasms

Australia, Hong Kong
Göteborg University
Umeå University

Completed

Comprehensive Geriatric Assessment for Frail Older People

Dependency

Sweden
German Breast Group
AstraZeneca; Celgene

Completed

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)

Breast Cancer

Germany
AbbVie

Terminated

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Cancer | Non Small Cell Lung Cancer

United States
University of Wisconsin, Madison
Madison Vaccines Incorporated

Completed

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Prostate Cancer

United States
University Hospital, Bordeaux
University of Bordeaux

Completed

Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder Cancer (IMMUN VESSIE)

Bladder Cancer

France
Assiut University

Unknown

Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain

Chronic Pain

Egypt
Assistance Publique - Hôpitaux de Paris

Completed

Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin (CARSKIN)

Carcinoma, Squamous Cell

France
Tetherex Pharmaceuticals Corporation

Completed

Study to Assess the Safety and Efficacy of SelK2 to Prevent Blood Clots in Patients Undergoing Total Knee Replacement (COURSE)

Venous Thromboembolism

Poland, Bulgaria, Latvia, Lithuania, Ukraine
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)

Breast Cancer
Duke University

Completed

Effects of Connectivity-based rTMS and State-Dependency on Amygdala Activation (ConnecTMS)

Amygdala Activation

United States
Catalyst Pharmaceuticals, Inc.

Terminated

Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence

Methamphetamine Dependence

United States
Assiut University

Unknown

Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer

Programmed Cell Death 1

Egypt
Jonsson Comprehensive Cancer Center

Completed

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer (MSG PSMA PET)

Prostate Carcinoma

United States
Daiichi Sankyo, Inc.
Syneos Health

Completed

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

Fibromyalgia

Spain, United States, Poland, Bulgaria, South Africa, Hungary, Czechia, Romania
Nantes University Hospital

Unknown

Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy

Bullous Pemphigoid | Immunotherapy | Programmed Cell Death Ligand 1

France
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Disulfiram for Cocaine Abuse in Buprenorphine Treatment

Opioid Dependency | Cocaine Dependence

United States
Advanced Accelerator Applications

Completed

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa) (PROfind)

Prostate Cancer Metastatic

United States
Mayo Clinic

Terminated

Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand

Ovarian Cancer

United States
Nucorion Pharmaceuticals, Inc.
Medpace, Inc.; Ligand Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects

Hepatitis B

United States
Dana-Farber Cancer Institute

Withdrawn

Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas

Soft Tissue Sarcoma

United States
Jonsson Comprehensive Cancer Center

Completed

Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery (PSMA vs AXUMIN)

Recurrent Prostate Carcinoma

United States
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Unknown

The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.

Antibiotic

China
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)

Triple Negative Breast Neoplasms
San Diego State University
United States Naval Medical Center, San Diego

Completed

Alcohol Screening, Brief Intervention, and Referral to Treatment in a Military Treatment Facility

Alcohol Dependency

United States
Kiang Wu Hospital

Completed

PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Federal University of São Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo; Conselho Nacional de...

Completed

Effectiveness of Mindfulness Based Relapse Prevention for Tobacco Dependents (MBRP)

Tobacco Use Disorder

Brazil
Johns Hopkins University

Completed

Buspirone for Opioid Tapering

Opioid-Related Disorders | Pain, Chronic | Dependency (Psychology) | Opiate Withdrawal Syndrome

United States
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
Duke University

Completed

An Opioid Prescribing Nudge (OHS)

Health Behavior | Opioid Use, Unspecified | Benzodiazepine Abuse | Prescription Drug Abuse (Not Dependent) | Benzodiazepine Dependent | Prescription Drug Abuse and Dependency

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Melanoma
Massachusetts General Hospital
Cedars-Sinai Medical Center; ALS Association; The Methodist Hospital Research...

Completed

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis (TRACK-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

Malignant Melanoma
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

PD-L1 Positive Non-small Cell Lung Cancer
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Chronic Pain and Opioid Dependence Assessment and Treatment (CPODAT)

Chronic Pain | Opioid Dependency

United States
Hospices Civils de Lyon

Unknown

Validation of a SOFMER Activity Scale (SAS)

Patients Hospitalized in a FRC Department

France
Groupe Français de Pneumo-Cancérologie

Completed

Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC)

Large Cell Lung Cancer | Neuroendocrine Carcinoma of Lung (Diagnosis)

France
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand

Hypoglycemia

United States
Yale University

Terminated

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Asymptomatic Myeloma

United States
Assiut University

Unknown

Immunohistochemical Assessment of Programmed Death ligand1 and LC3B in GBM

Glioblastoma Multiforme
Hoffmann-La Roche

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors

Solid Tumor

United States, Spain, Canada, United Kingdom, Denmark, France, Germany, Israel, Italy, Netherlands, Switzerland
Weill Medical College of Cornell University
The Institute for Family Health; New York State Health Foundation

Completed

Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients

Opioid-Related Disorders | Opioid Use | Opioid Abuse | Prescription Drug Abuse and Dependency

United States
Merck Sharp & Dohme LLC

Withdrawn

First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study

Esophageal Neoplasms

China
Assistance Publique - Hôpitaux de Paris

Unknown

NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL) (NADRANK-1)

Diabetes type2 | NAFLD | NASH - Nonalcoholic Steatohepatitis
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (CLIPA)

Leukemia | Leukemia, B-Cell, Chronic

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine

Leukemia

United States
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (BIRCH)

Non-Small Cell Lung Cancer

United States, Belgium, Hong Kong, Italy, Slovenia, Australia, Canada, Bulgaria, Germany, France, Georgia, Singapore, Spain, Bosnia and Herzegovina, Switzerland, Turkey, Japan, United Kingdom, Netherlands
Hoffmann-La Roche

Completed

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma (IMmotion150)

Renal Cell Carcinoma

United States, Spain, Czechia, United Kingdom, Romania, France, Italy, Germany, Poland
National Institute on Drug Abuse (NIDA)
University of Maryland, College Park

Completed

Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence

Schizophrenia | Drug Abuse/Dependency

United States

3

Subscribe